Vanguard Personalized Indexing Management LLC Purchases 2,175 Shares of ResMed Inc. (NYSE:RMD)

Vanguard Personalized Indexing Management LLC lifted its holdings in ResMed Inc. (NYSE:RMD) by 11.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,588 shares of the medical equipment provider’s stock after purchasing an additional 2,175 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in ResMed were worth $3,895,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in RMD. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of ResMed by 24.9% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,083 shares of the medical equipment provider’s stock valued at $35,068,000 after buying an additional 35,273 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in ResMed by 8.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 536,459 shares of the medical equipment provider’s stock valued at $92,285,000 after acquiring an additional 40,605 shares in the last quarter. Mediolanum International Funds Ltd bought a new stake in shares of ResMed in the 1st quarter worth approximately $2,246,000. Janney Montgomery Scott LLC grew its holdings in shares of ResMed by 5.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 81,313 shares of the medical equipment provider’s stock worth $16,102,000 after purchasing an additional 4,075 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its position in shares of ResMed by 3,599.0% during the first quarter. Los Angeles Capital Management LLC now owns 499,031 shares of the medical equipment provider’s stock valued at $98,823,000 after purchasing an additional 485,540 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Trading Up 2.1 %

NYSE RMD opened at $242.95 on Friday. The company has a market cap of $35.70 billion, a PE ratio of 37.32, a PEG ratio of 2.50 and a beta of 0.69. ResMed Inc. has a 12 month low of $132.24 and a 12 month high of $255.18. The stock has a 50 day moving average of $226.11 and a 200-day moving average of $208.77. The company has a current ratio of 2.59, a quick ratio of 1.69 and a debt-to-equity ratio of 0.14.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.05. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.60 EPS. On average, equities research analysts anticipate that ResMed Inc. will post 8.92 EPS for the current fiscal year.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th were issued a $0.53 dividend. The ex-dividend date was Thursday, August 15th. This represents a $2.12 dividend on an annualized basis and a yield of 0.87%. This is an increase from ResMed’s previous quarterly dividend of $0.48. ResMed’s payout ratio is currently 32.57%.

Insiders Place Their Bets

In other news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $192.97, for a total value of $2,833,378.51. Following the completion of the sale, the chief executive officer now directly owns 440,799 shares in the company, valued at $85,060,983.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $239.90, for a total transaction of $479,800.00. Following the sale, the director now directly owns 87,204 shares of the company’s stock, valued at approximately $20,920,239.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Michael J. Farrell sold 14,683 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $192.97, for a total value of $2,833,378.51. Following the completion of the transaction, the chief executive officer now owns 440,799 shares in the company, valued at approximately $85,060,983.03. The disclosure for this sale can be found here. Insiders have sold a total of 102,931 shares of company stock worth $22,644,807 in the last quarter. Corporate insiders own 1.21% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Royal Bank of Canada increased their price objective on shares of ResMed from $204.00 to $206.00 and gave the company a “sector perform” rating in a research note on Friday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research note on Wednesday. Wolfe Research restated an “underperform” rating and set a $180.00 target price on shares of ResMed in a research report on Wednesday. Oppenheimer lowered ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Finally, StockNews.com lowered ResMed from a “buy” rating to a “hold” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, ResMed currently has an average rating of “Hold” and an average price target of $199.70.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.